Investments
133Portfolio Exits
35Funds
12Partners & Customers
2About Forbion Capital Partners
Forbion Capital Partners invests in Life Sciences and Biomedical Technology companies developing drugs and technologies, with a clear focus on product development. The Forbion team is specialized in the evaluation of late stage preclinical / early stage clinical development programs. Forbion also invests in medical device companies with a focus on interventional cardiology and gastroenterology. The Forbion team began operating in 2000 as ABN AMRO Capital Life Sciences, the venture arm of ABN AMRO Bank NV. In December 2006 the group broadened its investor base, became independent, and changed its name to Forbion Capital Partners. Forbion currently has EUR 200 million under management.
Want to inform investors similar to Forbion Capital Partners about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Forbion Capital Partners
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Forbion Capital Partners in 1 Expert Collection, including CB Insights Healthcare Smart Money Investors - 2020.
CB Insights Healthcare Smart Money Investors - 2020
25 items
Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.
Research containing Forbion Capital Partners
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Forbion Capital Partners in 4 CB Insights research briefs, most recently on Feb 16, 2021.
Latest Forbion Capital Partners News
Mar 16, 2022
16/03/2022 - 08:00 | Portfolio Brussels, Belgium, 16 March 2022 – Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a EUR 80m Series B financing round led by new investor INKEF Capital, alongside Jeito Capital and Forbion Capital Partners. The company’s existing shareholders Gimv, HealthCap, Novo Holdings, Pontifax Venture Capital, V-Bio Ventures, BioMed Partners, as well as the seed investors, continue to support the company and participated in the round. The proceeds of this financing round will fund the development and expansion of Precirix’ pipeline. More specifically, the company will advance CAM-H2 through its ongoing Phase I/II study and plans to bring additional novel radiopharmaceuticals to the clinic. Michaël Vlemmix, Principal in Gimv’s Health & Care platform and board member indicates: “Precirix has made significant progress since its Series A in 2018. The additional financing will allow us to further leverage the radiopharmaceutical platform, diversify the pipeline and continue to advance the clinical developments with a core goal to bring new medicines to patients. Backed by some of the strongest names in our industry, the company holds a solid foundation to further build on its story towards success”. For more information, please read the full press release from Precirix attached.
Forbion Capital Partners Investments
133 Investments
Forbion Capital Partners has made 133 investments. Their latest investment was in Complement Therapeutics as part of their Series A on April 4, 2023.
Forbion Capital Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
4/17/2023 | Series A | Complement Therapeutics | $79.09M | No | 9 | |
3/16/2023 | Seed | Seamless Therapeutics | $8.5M | Yes | 5 | |
3/7/2023 | Series B | Noema Pharma | $112M | Yes | Forbion Capital Partners, Gilde Healthcare, Invus Group, Jeito Capital, Polaris Partners, Sofinnova Partners, Undisclosed Investors, and UPMC Enterprises | 5 |
11/22/2022 | Series C | |||||
10/17/2022 | Series C |
Date | 4/17/2023 | 3/16/2023 | 3/7/2023 | 11/22/2022 | 10/17/2022 |
|---|---|---|---|---|---|
Round | Series A | Seed | Series B | Series C | Series C |
Company | Complement Therapeutics | Seamless Therapeutics | Noema Pharma | ||
Amount | $79.09M | $8.5M | $112M | ||
New? | No | Yes | Yes | ||
Co-Investors | Forbion Capital Partners, Gilde Healthcare, Invus Group, Jeito Capital, Polaris Partners, Sofinnova Partners, Undisclosed Investors, and UPMC Enterprises | ||||
Sources | 9 | 5 | 5 |
Forbion Capital Partners Portfolio Exits
35 Portfolio Exits
Forbion Capital Partners has 35 portfolio exits. Their latest portfolio exit was New Amsterdam Pharma on November 22, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
11/22/2022 | Reverse Merger | 4 | |||
12/22/2021 | Acquired | 19 | |||
11/22/2021 | Acquired | 6 | |||
Date | 11/22/2022 | 12/22/2021 | 11/22/2021 | ||
|---|---|---|---|---|---|
Exit | Reverse Merger | Acquired | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 4 | 19 | 6 |
Forbion Capital Partners Fund History
12 Fund Histories
Forbion Capital Partners has 12 funds, including Forbion Growth Opportunities Fund II.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
6/9/2022 | Forbion Growth Opportunities Fund II | $500M | 1 | ||
4/20/2021 | Forbion Growth Opportunities Fund I | $428M | 1 | ||
12/8/2020 | Forbion V | $557.1M | 4 | ||
7/9/2020 | Forbion Growth Fund | ||||
10/1/2018 | Forbion IV |
Closing Date | 6/9/2022 | 4/20/2021 | 12/8/2020 | 7/9/2020 | 10/1/2018 |
|---|---|---|---|---|---|
Fund | Forbion Growth Opportunities Fund II | Forbion Growth Opportunities Fund I | Forbion V | Forbion Growth Fund | Forbion IV |
Fund Type | |||||
Status | |||||
Amount | $500M | $428M | $557.1M | ||
Sources | 1 | 1 | 4 |
Forbion Capital Partners Partners & Customers
2 Partners and customers
Forbion Capital Partners has 2 strategic partners and customers. Forbion Capital Partners recently partnered with Lonza Group, and BioGeneration Ventures on December 12, 2020.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
12/14/2020 | Vendor, and Client | Switzerland, and Netherlands | Forbion operates a joint venture with BioGeneration Ventures , the manager of seed and early-stage funds , especially focused on Benelux and Germany . | 1 | |
12/10/2020 | Partner |
Date | 12/14/2020 | 12/10/2020 |
|---|---|---|
Type | Vendor, and Client | Partner |
Business Partner | ||
Country | Switzerland, and Netherlands | |
News Snippet | Forbion operates a joint venture with BioGeneration Ventures , the manager of seed and early-stage funds , especially focused on Benelux and Germany . | |
Sources | 1 |
Forbion Capital Partners Team
14 Team Members
Forbion Capital Partners has 14 team members, including current Chief Financial Officer, Vincent Van Houten.
Name | Work History | Title | Status |
|---|---|---|---|
Vincent Van Houten | Chief Financial Officer | Current | |
Name | Vincent Van Houten | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Chief Financial Officer | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
